Filing Flows

Filing Flows › Fate Therapeutics (FATE) › Next earnings date

Fate Therapeutics (FATE) earnings: beat the estimate

Fate Therapeutics (FATE) reported on Nov 5, 2026 and beat the EPS estimate: −$0.25 against −$0.26 (+2.0%). It beat the EPS estimate in 100% of the quarters on record.

Last result+2.0% vs estimate
Beat rate100%

The last report

Fate Therapeutics reported revenue of $2.1M for the second quarter 2026 (+9% Y/Y), net loss $30.2M. How it makes money → · Every quarter →

Fate Therapeutics: EPS against the estimate, last 5 reportsFate Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.28−$0.27Nov 25−$0.27−$0.27Feb 26−$0.28−$0.26May 26−$0.26−$0.25Aug 26−$0.26−$0.25Nov 26
Latest (Nov 26): Estimate −$0.26, Reported −$0.25.

Fate Therapeutics' latest quarter

Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Fate Therapeutics beat earnings?

Fate Therapeutics (FATE) reported on Nov 5, 2026 and beat the EPS estimate: −$0.25 against −$0.26 (+2.0%).

When does FATE report earnings?

The next date is not set yet.

Does Fate Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.